The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
@ Lionel
yes we're talking about the same document the link on the history page has the date as 9 Feb 2023 but that could very well be the date it was first added to the site. i can't seem to find the date stamp of 21 Dec 2023 anywhere.
As far as I can see this document is from Feb 2023 not this year and relates to the Genedrive MT-RNR1 ID Kit.
The linked document can be found on the history section which has all the relevant documents listed.
https://www.nice.org.uk/guidance/hte6/history
@ unhooked. It's not a SEMI- Update ( although I did also read it that way). Turns out that the company has changed its name to Alphawave Semi lol. Not been following the stock so not sure when this changed.
https://awavesemi.com/
Are we sure it will be positive news. What info are we basing this on?
https://www.thetimes.co.uk/article/investors-dump-darktrace-after-cybersecurity-firm-warns-of-impending-share-sale-by-staff-mgxt6n7zt
@ pearls
That's why some have sold.
https://sharetipstersuncovered.wordpress.com/category/tom-winnifrith/
More info (older article from 2015)
ASX ANNOUNCEMENT
23 March 2022
www.88energy.com
Ground Floor, 516 Hay Street, Subiaco WA 6008 PO Box 352, Subiaco WA 6904 Australia Phone +61 8 9485 0990
ABN 80 072 964 179
This announcement contains inside information
88 Energy Limited
Merlin-2 Well Reaches Total Depth
Highlights
• Merlin-2 has successfully reached Total Depth of 7,334 feet and drilling has now ceased.
• All three (3) target reservoirs in the Merlin-2 well were penetrated with elevated gas readings.
• Observations of cuttings samples have revealed oil shows (under both white and ultraviolet light)
over all target intervals.
• Wireline logging is set to commence shortly to confirm whether mobile hydrocarbons are present
as well as to evaluate the reservoir quality and flow potential of target zones.
88 Energy Limited (ASX:88E, AIM:88E, OTC:EEENF) (88 Energy or the Company) is pleased to report
that the Merlin-2 appraisal well has reached Total Depth (TD) of 7,334 feet on 22 March 2022 (Alaskan
time) and drilling has now ceased. The Arctic Fox rig has exceeded expectations in terms of drilling
performance, with the well reaching TD safely and efficiently.
All three Nanushuk targets (N20, N19 and N18) were penetrated during drilling, with Logging While
Drilling (LWD) data and physical cuttings collected throughout the Merlin-2 program.
Initial observations of LWD logs and drill cuttings collected throughout the drilling operations revealed
target intervals are thicker than those encountered in Merlin-1 as anticipated pre-drill, with oil shows
noted under white light in the three target Nanushuk reservoirs. Fluorescence has also been observed
in numerous samples when placed under an ultraviolet light, an indication of oil presence. Additionally,
when solvent was applied to the fluorescing samples, “moderately fast” to “immediate and blooming”
“cuts” were noted, the speed of which is often a proxy for sample permeability.
Finally, significant mud gas
peaks were detected across all
target sequences in the
Nanushuk, with marked
increases in the heavier carbon
compounds (C2-C5) observed in
each. Further and more detailed
analysis will be conducted on the
mud gas samples upon the mud
gas isotube delivery to 88
Energy’s preferred lab.
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02501901-6A1083046?access_token=83ff96335c2d45a094df02a206a39ff4
Emailed Walbrook and their reply:
Good afternoon
I’ve recently read a document published by the DOD (link below) relating to their budgeting, which refers to some Genedrive products.
It mentions delivery will be in June 2022 (page 81)
It also adds comments to say that it is being developed by Epistem (page 79).
I was hoping that it could be clarified as to whether Genedrive still involved with this project or is this solely with Epistem, which I understand to be now separate from Genedrive.
Thanks in advance.
Reply:
Gendrive used to trade under the name Epistem. Genedrive used to have a contract research business that was sold in 2018 and now trades as Epistem. The Company has not had any Purchase Orders or commitments from the DoD. The Company is in the same position as detailed in the preliminary results in November - they have had no news and because of that a positive outcome is unlikely.
Regards,
Anna
Bedhead- The lowest constituent of the FTSE 250 has a much lower MCap than POLY. So while their Mcap is low enough to fall out of the FTSE100 they could still be within the FTSE250 based on Mcap alone.
I believe the issue is due to lack of liquidity which makes it hard for instis to buy in the amounts they need. Other can correct if I'm wrong on this but it makes sense to me as I've struggled to buy even £1ks worth a lot of the time.